Clinical trials: Ampullary Neoplasm, active
Adenocarcinoma of the Pancreas, Adenocarcinoma of the Duodenum
Efficacy and Safety of TPIAT for Resectable Adenocarcinoma of the Pancreas Region at High Risk of Postoperative Fistula
Curative management of locally resectable invasive adenocarcinomas located in the cephalic region of the pancreas (pancreas, duodenum and ampulla of Vater) requires a pancreaticoduodenectomy followed by adjuvant chemotherapy.
- Conditions
- Adenocarcinoma of the Pancreas, Adenocarcinoma of the Duodenum, Ampullary Adenocarcinoma
- Trial name
- TPIAT-01 (NCT05116072)
- Testing
- total pancreatectomy, intraportal islet autotransplantation
- Where
- France
- Volunteers
- 36 people
- Sponsor
- University Hospital, Lille
Ampulla of Vater Neoplasms, Ampullary Adenoma
Effect of Negative-Pressure Drainage Versus Pancreatic Duct Stenting for Preventing Pancreatitis After Endoscopic Papillectomy for Duodenal Papillary Tumors
This prospective, multicenter, randomized controlled trial aims to evaluate the effectiveness of negative-pressure duodenal drainage compared with prophylactic pancreatic duct stenting in preventing post-endoscopic papillectomy…
- Conditions
- Ampulla of Vater Neoplasms, Ampullary Adenoma, Ampullary Carcinoma
- Trial name
- NCT07446543
- Testing
- Placement of a negative pressure drainage tube, Placement of a pancreatic duct stent
- Volunteers
- 132 people
- Sponsor
- Cui Xiaobing
Uterine Neoplasms, Uterine Cervical Neoplasms
Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations
This trial studies how well tucatinib works for solid tumors that make either more HER2 or a different type of HER2 than usual (HER2 alterations) The solid tumors studied in this trial have either spread to other parts of the…
- Conditions
- Uterine Neoplasms, Uterine Cervical Neoplasms, Biliary Tract Neoplasms, Urologic Neoplasms
- Trial name
- NCT04579380
- Testing
- tucatinib, trastuzumab, fulvestrant
- Where
- 108 sites in United States, Belgium and 6 more
- Volunteers
- 217 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Biliary Tract Cancer, Cholangiocarcinoma
A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
This is a multi-center, open-label, randomized, phase 2/3 trial of the bispecific antibody CTX-009 plus paclitaxel versus paclitaxel in patients with previously treated, unresectable advanced or metastatic biliary tract cancers.
- Conditions
- Biliary Tract Cancer, Cholangiocarcinoma, Gall Bladder Cancer, Ampullary Cancer
- Trial name
- NCT05506943
- Testing
- CTX-009, Paclitaxel
- Where
- 33 sites in United States
- Volunteers
- 168 people
- Sponsor
- Compass Therapeutics
Pancreas Cancer With Hepatic Metastase, Pancreas Adenocarcinoma
Hepatic Artery Infusion Pump Chemotherapy for Liver Metastases From Resected Pancreatic and Duodenal Adenocarcinoma
The goal of this observational study is to evaluate whether hepatic artery infusion pump (HAIP) chemotherapy can improve outcomes in patients with pancreatic or duodenal adenocarcinoma who have isolated or liver-dominant…
- Conditions
- Pancreas Cancer With Hepatic Metastase, Pancreas Adenocarcinoma, Duodenal Cancer, Duodenal Adenocarcinoma
- Trial name
- NCT07845617
- Testing
- Hepatic Artery Infusion Pump (HAIP), Floxuridine (FUDR)
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- AdventHealth
Pancreatic Cancer
ToPanc Trial: Survival After Total Versus Partial Pancreaticoduodenectomy for Adenocarcinoma of the Pancreatic Head, Distal Cholangiocarcinoma, and Ampullary Cancer
The goal of this clinical trial is to learn if total removal of the pancreas is a preferable alternative to partial removal in patients with cancer of the pancreatic head who are at high risk of pancreatic leakage.
- Trial name
- ToPanc (NCT06801899)
- Testing
- Total pancreatectomy (TP), Partial pancreaticoduodenectomy (PD)
- Where
- 10 sites in Germany, Switzerland
- Volunteers
- 170 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Peri-ampullary Tumor
Complete vs. Postoperative Nasogastric Tube Omission in Pancreaticoduodenectomied Patients
Enhanced recovery after surgery (ERAS) programs recommend early removal of a nasogastric tube ( NGT) after operation has been suggested in elective major abdominal surgery, such as colorectal3, gastric4, and hepatic surgery5.
- Trial name
- PDNONG (NCT07321470)
- Testing
- Thick needle suction, PONGT
- Where
- Taiwan
- Volunteers
- 240 people
- Sponsor
- National Taiwan University Hospital
Hepatobiliary Cancer, Pancreatic Cancer
Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
This is a prospective pilot protocol investigating whether ctDNA detection be improved by sampling the cancer draining vein versus the standard practice of sampling from a peripheral vein in patients who are undergoing biopsies…
- Conditions
- Hepatobiliary Cancer, Pancreatic Cancer, Hepatocellular Carcinoma, Cholangiocarcinoma
- Trial name
- NCT05497531
- Testing
- ctDNA Blood Collection
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, Irvine
Ampullary Neoplasm, Ampullary Adenoma
Endoscopic Papillectomy Versus Surgery for Ampullary Tumors: A Prospective Multicenter Cohort Study
The aim of this study is to compare the efficacy and safety of endoscopic treatment (endoscopic papillectomy [EP] with or without intraductal radiofrequency ablation [RFA]) and surgical treatment (transduodenal ampullectomy [TSA]…
- Trial name
- NCT07915726
- Testing
- Endoscopic treatment group, Surgical treatment group
- Where
- China
- Volunteers
- 306 people
- Sponsor
- Qilu Hospital of Shandong University
Ampullary Cancer, Bile Duct Cancer
Modified vs Conventional Blumgart Anastomosis of LPD for the Effects of Pancreatic Fistula of Periampullary Carcinoma
The incidence rate and mortality rate of periampullary cancer at home and abroad both show an increasing trend, seriously affecting the health level of the people.
- Conditions
- Ampullary Cancer, Bile Duct Cancer, Pancreas Cancer, Duodenum Cancer
- Trial name
- NCT06076252
- Testing
- Modified Blumgart Anastomosis in LPD, conventional Blumgart anastomosis in LPD
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Affiliated Hospital of Guangdong Medical University
Pancreas Cancer, Periampullary Cancer
Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer
Adjuvant chemotherapy after surgery significantly improved the survival of pancreatic cancer (PC) patients, but there is a problem that only about 50% of patients start adjuvant chemotherapy after pancreatectomy.
- Conditions
- Pancreas Cancer, Periampullary Cancer, Periampullary Carcinoma Resectable, Pancreatic Cancer Resectable
- Trial name
- NCT07081360
- Testing
- Neoadjuvant chemotherapy, Upfront Surgery Group
- Where
- Egypt
- Volunteers
- 262 people
- Sponsor
- Minia University
Ampullary Adenocarcinoma
The ADAPTA Study: ADjuvant chemotherAPy After Curative Intent resecTion of Ampullary Cancer.
Ampullary adenocarcinoma (AAC) is a rare gastrointestinal cancer with varying survival rates, particularly the aggressive pancreatobiliary (PB) subtype.
- Trial name
- ADAPTA (NCT06068023)
- Testing
- Folfirinox, Capox
- Where
- Italy
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Fondazione Poliambulanza Istituto Ospedaliero
Pancreatic Ductal Adenocarcinoma, Ampullary Carcinoma
Outcomes After Laparoscopic Versus Open Pancreaticoduodenectomy
This is a monocentric, prospective, randomized controlled trial comparing the safety and efficacy of laparoscopic pancreaticoduodenectomy (LPD) versus open pancreaticoduodenectomy (OPD).
- Conditions
- Pancreatic Ductal Adenocarcinoma, Ampullary Carcinoma, Distal Cholangiocarcinoma, Duodenal Adenocarcinoma
- Trial name
- NCT07328607
- Testing
- Open Pancreaticoduodenectomy, Laparoscopic Pancreaticoduodenectomy
- Where
- Egypt
- Volunteers
- 90 people
- Sponsor
- Minia University
Cancer Pain, Visceral Pain
Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
Patients with digestive tract malignancy often experience severe and unremitting abdominal pain that negatively affects physical, emotional, and social function, as well as health related quality of life (HRQOL).
- Conditions
- Cancer Pain, Visceral Pain, Gastrointestinal Neoplasms, Cancer of Gastrointestinal Tract
- Trial name
- NCT04907643
- Testing
- PICO G2 4k
- Where
- United States
- Volunteers
- 360 people
- Sponsor
- Cedars-Sinai Medical Center
Foregut Adenocarcinoma, Esophageal Adenocarcinoma
Trial Comparing Standard of Care Therapy With and Without Sequential Cytoreductive Intervention for Patients With Metastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels
This is a randomized, open label, single-center, phase 2, randomized controlled trial of sequential cytoreductive intervention versus standard of care therapy for patients with intervenable oligometastatic (stage IV) cancer of…
- Conditions
- Foregut Adenocarcinoma, Esophageal Adenocarcinoma, Gastroesophageal Adenocarcinoma, Gastric Adenocarcinoma
- Trial name
- OLIGOMETS (NCT07282912)
- Testing
- Sequential cytoreductive intervention, Signatera Genome ultra-sensitive ctDNA blood test
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- Yale University
Hepatobiliary Cancer, Pancreatic Cancer
Impact of Comprehensive Geriatric Management on Morbidity and Quality of Life in Elderly Patients Undergoing Major Hepatectomy and Pancreaticoduodenectomy for Cancer
The worldwide incidence of hepatobiliary and pancreatic (HPB) cancers is dramatically increasing especially for pancreatic cancer. Increasing age is associated with increased cancer risk.
- Trial name
- HPB70+ (NCT06999512)
- Testing
- Comprehensive Geriatric Assessment
- Where
- 12 sites in France
- Volunteers
- 526 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Advanced Solid Tumors, HER2 Mutation
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Researchers are looking for a better way to treat people who have solid tumors with HER2-activating mutations. Before a treatment can be approved for people to take, researchers do clinical trials to better understand its safety…
- Trial name
- panSOHO (NCT06760819)
- Testing
- BAY2927088
- Where
- 54 sites in United States, Australia and 9 more
- Volunteers
- 111 people
- Sponsor
- Bayer
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC)
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics (PK) of escalating doses of RMC-6291 (KRAS G12C(ON) inhibitor) monotherapy in adult subjects with advanced solid tumors and to identify the…
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor
- Trial name
- NCT05462717
- Testing
- RMC-6291
- Where
- 64 sites in United States, Australia and 11 more
- Volunteers
- 222 people
- Sponsor
- Revolution Medicines, Inc.
Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
This study is to evaluate the safety, tolerability, and PK profiles of Elironrasib and Daraxonrasib as monotherapies and combination therapy in patients with KRAS G12C-mutated solid tumors.
- Conditions
- Non-Small Cell Lung Cancer (NSCLC), Colorectal Cancer, Pancreatic Ductal Adenocarcinoma
- Trial name
- NCT06128551
- Testing
- Elironrasib, Daraxonrasib
- Where
- 56 sites in United States, France and 5 more
- Volunteers
- 534 people
- Sponsor
- Revolution Medicines, Inc.
Duodenal Adenoma, Duodenal Carcinoma
Analysis of Long-term Outcomes of Endoscopic Resection of Duodenal and Ampullary Mucosal and Submucosal Lesions
Mucosal and submucosal lesions of the duodenum represent a diverse group of pathologies, ranging from benign adenomas to lesions with significant malignant potential.
- Conditions
- Duodenal Adenoma, Duodenal Carcinoma, Papillary Adenoma, Papillary Adenocarcinoma
- Trial name
- DuoP-ER (NCT07781137)
- Where
- Australia
- Volunteers
- 1,000 people
- Sponsor
- Western Sydney Local Health District